ATNM-400 is advancing as a first-in-class, multi-tumor Actinium-225 radiotherapy candidate with activity across prostate and lung cancers, two of the largest cancer indications globally New preclinical findings demonstrate ATNM-400 overcomes resistance to the EGFR inhibitor osimertinib in...
Hence then, the article about actinium pharmaceuticals to unveil the multi tumor potential of atnm 400 a first in class actinium 225 radiotherapy with data in non small cell lung cancer at the aacr nci eortc international conference on molecular targets and cancer the was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer The )
Also on site :
- 'Love Island USA': Carl Defends Trinity After Recoupling Argument With Tierra
- Trump threatens Iran ‘will no longer exist’ for ceasefire violation
- 1972 Rock Classic, Never Recorded in the Studio, Remains a Timeless 4th of July Anthem 54 Years Later